Shots:

• The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (1200mg) + Avastin (15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg- bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC- prior not treated with systemic therapies
• Results: @median follow-up of 15.6mos.- 34% reduction in OS; m-OS (19.2 vs 13.4mos.); mPFS (6.9 vs 4.3mos.). In Chinese population- m-OS (24.0 vs 11.4mos.)
• Tecentriq + Avastin is an approved therapy across the globe- including in the US- China- Japan and the EU- for people with unresectable HCC and is recommended in many clinical practice guidelines globally

 ­ Ref: Roche | Image: Roche